[go: up one dir, main page]

WO2024075067A1 - Composition de vaccin contre le cancer qui comprend une cellule hôte exprimant le glypican-1 (gpc-1) - Google Patents

Composition de vaccin contre le cancer qui comprend une cellule hôte exprimant le glypican-1 (gpc-1) Download PDF

Info

Publication number
WO2024075067A1
WO2024075067A1 PCT/IB2023/060036 IB2023060036W WO2024075067A1 WO 2024075067 A1 WO2024075067 A1 WO 2024075067A1 IB 2023060036 W IB2023060036 W IB 2023060036W WO 2024075067 A1 WO2024075067 A1 WO 2024075067A1
Authority
WO
WIPO (PCT)
Prior art keywords
host cell
tumour
use according
glypican
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2023/060036
Other languages
English (en)
Inventor
Giuseppe TOFFOLI
Michele DAL BO
Idris VRUZHAJ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro di Riferimento Oncologico
Original Assignee
Centro di Riferimento Oncologico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro di Riferimento Oncologico filed Critical Centro di Riferimento Oncologico
Publication of WO2024075067A1 publication Critical patent/WO2024075067A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Definitions

  • the present invention relates to a compound selected from a polynucleotide coding for Glypican-1 , a vector, and a host cell genetically engineered so as to express Glypican-1.
  • the present invention further relates to the use of the compound for the prevention or treatment of a tumour.
  • TTAs tumor-associated antigens
  • a first aspect of the present invention relates to a genetically engineered host cell comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 1 , or a vaccine composition comprising said host cell, for use in eliciting an immune response against Glypican-1 (GPC-1 ) in an individual and/or in the treatment or prevention of a tumour, wherein the host cell is a bacterial cell and wherein the host cell or the composition is administered orally.
  • the nucleotide sequence is identical to SEQ ID NO:1.
  • the host cell is a probiotic bacterium.
  • the host cell belongs to the genus Escherichia and/or Bifidobacterium and/or Lactobacillus', more preferably, the host cell belonging to the genus Escherichia belongs to the species E. Coli Nissle, wherein the host cell belonging to the genus Bifidobacterium belongs to the species B. longum or B. infantis or B. clausii, and wherein the host cell belonging to the genus Lactobacillus belongs to the species L reuteri, L acidophilus, L casei, L lactis, L plantarum and combinations thereof.
  • the tumour is a solid tumour; it is preferably a tumour that expresses Glypican-1 and, more preferably, it is a tumour that overexpresses Glypican-1 .
  • the tumour is selected from: glioblastoma, prostate cancer, oesophageal cancer, pancreatic cancer, and breast cancer; the tumour is preferably pancreatic carcinoma and, more preferably, it is pancreatic ductal adenocarcinoma.
  • the host cell or vaccine composition for the medical uses specified above is administered in association or in combination with at least one drug or a therapy to treat or prevent the tumour.
  • the at least one drug is selected from temozolamide, paclitaxel, nab- paclitaxel, folfirinox, epirubicin, capecitabine, oxaliplatin, prostate hormone therapy, and EGFR inhibitor drugs and wherein the at least one therapy is surgery or radiotherapy.
  • the composition is formulated for oral administration; more preferably, it is formulated as a solution, tablet, capsule, pill, granular powder, hard-shelled capsule, orodispersible granules, sachets, lozenges, or drinkable vials.
  • Figure 1 shows a Ponceau red staining of a blot with transferred proteins of E. Coli Nissle (A); and an immunoblotting with anti-GPC1 antibody diluted 1 :5000 (B).
  • the marker was loaded into well 1 ; the total lysates of E. Coli Nissle transformed with the vector containing the gene of interest were loaded into wells 2 and 3, and the lysates of E. Coli Nissle WT were loaded into wells 4 and 5.
  • Figure 2 shows a histogram with the mean count of mouse serum positivity for BxPC3 and Jurkat cells assessed by flow cytometry. Basal and after 19 days of treatment.
  • Figure 3 shows a histogram with the response of the mouse sera tested by ELISA to the antigen GPC1 .
  • a first aspect of the present invention relates to a compound selected from: a) a polynucleotide coding for Glypican-1 or for a portion of Glypican-1 , preferably comprising a nucleotide sequence at least 80% identical to SEQ ID NO: 1 ; b) a vector comprising said polynucleotide; and c) a genetically engineered host cell comprising said polynucleotide.
  • the polynucleotide comprises a nucleotide sequence that is substantially homologous or identical to SEQ ID NO.1 (Table 1 ).
  • the polynucleotide comprises a nucleotide sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous or identical to SEQ ID NO. 1 .
  • the polynucleotide comprises a nucleotide sequence at least 80%, more preferably at least 90%, homologous or identical to SEQ ID NO. 1 .
  • the polynucleotide consists in a nucleotide sequence that is substantially homologous or identical to SEQ ID NO.1.
  • the polynucleotide consists in a nucleotide sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous or identical to SEQ ID NO. 1 .
  • the polynucleotide consists in a nucleotide sequence at least 80%, more preferably at least 90%, homologous or identical to SEQ ID NO. 1 .
  • the polynucleotide comprises at least one sequence coding for a protein portion which enables the transfer and anchorage of the protein Glypican-1 on the outer part of the host cell.
  • the polynucleotide comprises at least one sequence coding for at least one portion of a bacterial flagellum, preferably coding for a flagellin. In one embodiment, the at least one portion of a bacterial flagellum is a portion of a flagellin of Salmonella enterica.
  • the vector comprising the above-described polynucleotide is selected from: viral vector, plasmid, viral particles, and phage.
  • the vector is a plasmid vector.
  • the genetically engineered host cell which expresses Glypican-1 or a portion of Glypican-1 is selected from: bacterial cell, fungal cell, animal cell, insect cell and plant cell; the host cell is preferably a bacterial cell.
  • the bacterial cell is a probiotic bacterium.
  • the host cell comprises a nucleotide sequence at least 90% identical to SEQ ID NO: 1 , more preferably identical to SEQ ID NO: 1.
  • the host cell is a bacterial cell belonging to the genus Escherichia and/or Bifidobacterium and/or Lactobacillus or another probiotic bacterium.
  • the host cell belonging to the genus Escherichia belongs to the species E. Coli Nissle
  • the host cell belonging to the genus Bifidobacterium belongs to the species B. longum or B. infantis or B. clausii
  • the host cell belonging to the genus Lactobacillus belongs to the species L reuteri, L acidophilus, L casei, L lactis, L plantarum and combinations thereof.
  • the host cell belonging to the genus Escherichia is the strain E. Coli Nissle 1917
  • the host cell belonging to the genus Bifidobacterium is B. longum
  • the host cell belonging to the genus Lactobacillus is L acidophilus.
  • the host cell preferably a bacterial cell, more preferably a probiotic, comprises the polynucleotide described above and expresses the human protein Glypican-1 .
  • the host cell is a bacterial cell comprising the polynucleotide described above and which expresses the protein Glypican-1 or a portion thereof on the bacterial membrane.
  • the host cell comprises the vector described above.
  • the polynucleotide described above is inserted into the vector and/or host cell with techniques known to the person skilled in the art, such as, for example, cloning techniques or techniques including the use of CRISPR/CAS technology.
  • a second aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the compound as described above in detail.
  • the composition is a vaccine composition, i.e. a vaccine.
  • the composition of the present invention can further comprise at least one pharmacologically acceptable excipient, i.e. a compound acceptable for pharmaceutical use which is useful in the preparation of the composition and is generally biologically safe and nontoxic.
  • the composition comprises the host cell which expresses Glypican-1 (or “GPC-1”) or a portion of Glypican-1 as described above.
  • the composition is formulated for oral administration.
  • the composition is formulated as a solution, tablet, capsule, pill, granular powder, hard-shelled capsule, orodispersible granules, sachets, lozenges, drinkable vials or in the form of suspensions in oil.
  • composition is formulated as a suppository.
  • the composition is formulated for administration by inhalation.
  • the composition is in lyophilised form in order to be reconstituted and obtain a liquid formulation.
  • the composition is formulated for parenteral administration, preferably as a solution, suspension, sterile emulsion, or powder to be 5 resuspended before use.
  • the composition is formulated for subcutaneous administration.
  • a third aspect of the present invention relates to the compound or composition as described above in detail for use as a medicament.
  • a fourth aspect of the present invention relates to the compound or composition as described above in detail or the human protein Glypican-1 or a portion thereof, for use in eliciting an immune response against Glypican-1 (GPC-1 ) in an individual and/or in the prevention or treatment of a tumour, preferably a malignant tumour.
  • GPC-1 Glypican-1
  • the human protein Glypican-1 comprises an amino acid sequence that is substantially identical to SEQ ID NO.2.
  • the human protein Glypican-1 comprises an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO. 2.
  • the human protein Glypican-1 comprises an amino acid sequence at least 80%, more preferably at least 90%, identical to SEQ ID NO. 2.
  • the human protein Glypican-1 consists in an amino acid sequence substantially identical to SEQ ID NO. 2.
  • the human protein Glypican-1 consists in an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO. 2.
  • the human protein Glypican-1 consists in an amino acid sequence at least 80%, more preferably at least 90%, identical to SEQ ID NO. 2.
  • the human protein Glypican-1 comprises modifications to the N-terminal and/or C-terminal region, for example such as to increase the immunogenicity of the protein. Said modifications are preferably selected from deletions, additions, alterations of amino acids and combinations thereof.
  • the protein Glypican-1 can be modified, preferably in its primary structure, by acetylation, carboxylation, phosphorylation, and combinations thereof.
  • said Glypican-1 is conjugated/bound with a molecule, a metal, or a marker, for example proteins, for the preparation of fusion proteins.
  • said Glypican-1 is modified by means of molecular biology techniques to improve its resistance to proteolytic degradation and/or to optimise its solubility or improve its pharmacokinetic characteristics.
  • said Glypican-1 can be modified for the purpose of facilitating or improving delivery, preferably by PEGylation, or using container/shuttle/carrier systems, preferably of the liposome, micelle, capsule, emulsion, matrix, or gel type and the like.
  • said Glypican-1 is coated with a structure capable of improving its stability and/or half-life and/or water solubility and/or immunological characteristics.
  • Said structure is for example a pH-sensitive microsphere, a microsphere, a micro-pill, a liposome, or nano-delivery systems with conductive particles mediated by pulsed electric fields (PEFs) or fusion with cell-penetrating peptides (CPPs).
  • PEFs pulsed electric fields
  • CPPs cell-penetrating peptides
  • the protein Glypican-1 is obtained by means of recombinant DNA techniques known to the person skilled in the art, preferably by cloning of the polynucleotide (cDNA) coding for Glypican-1 in a plasmid vector for the expression of the recombinant enzyme in bacteria.
  • cDNA polynucleotide
  • Glypican-1 is obtained by cloning of the polynucleotide coding for Glypican-1 comprising SEQ ID NO. 1 , as described above in detail.
  • said Glypican-1 is synthesised by means of conventional protein synthesis techniques known to the skilled person.
  • the protein can be synthesised by chemical synthesis using solid-phase peptide synthesis.
  • the protein Glypican-1 is isolated or purified with methods known to the person skilled in the art.
  • the protein Glypican-1 can be purified by means of biochemical methods, such as filtration, affinity, or immunoaffinity, or by means of high-performance liquid chromatography (HPLC, RP-HPLC, ion-exchange HPLC, size-exclusion HPLC).
  • the tumour preferably a malignant tumour, expresses the human protein Glypican-1.
  • the tumour is a tumour that overexpresses the human protein Glypican-1 .
  • the tumour is a solid tumour, preferably selected from: glioblastoma, prostate cancer, oesophageal cancer, pancreatic cancer, and breast cancer, preferably pancreatic carcinoma, even more preferably pancreatic ductal adenocarcinoma,
  • the compound is/the composition comprises the host cell that expresses Glypican-1 (or “GPC-1”) or a portion of Glypican-1 as described above.
  • the compound or composition or human protein Glypican-1 as described above in detail is administered orally or by inhalation.
  • the compound or composition or human protein Glypican-1 as described above in detail is administered orally, for example formulated as a spray for oral use or as a tablet or as orodispersible granules.
  • the compound or composition or human protein Glypican-1 as described above in detail is administered parenterally, preferably subcutaneously.
  • the Applicant has in fact surprisingly found that, by inserting a specific immunogenic sequence into a probiotic bacterium one generates an immunogenic response towards a specific tumour-associated antigen (TAA), Glypican-1.
  • TAA tumour-associated antigen
  • the immunogenic response against the antigen Glypican-1 makes the compound, composition and protein Glypican-1 described above in detail useful in combating and preventing some solid tumours, such as glioblastoma and pancreatic ductal adenocarcinoma.
  • the immune response against Glypican-1 generated with oral administration is wholly comparable to the immune response obtained with a subcutaneous administration of the compound and composition described above.
  • the protein Glypican-1 is not expressed in benign tumours or in non-cancerous tissues; therefore, the immune response generated by the vaccine is specific for the treatment of a tumour that expresses or overexpresses Glypican-1 .
  • the compound or composition or human protein Glypican-1 as described above in detail is used individually or in combination with at least one therapeutic treatment for the treatment of a tumour, preferably a malignant tumour.
  • the at least one therapeutic treatment for the treatment of a tumour is selected from: at least one chemotherapy drug, a surgical intervention for the removal and/or reduction of the tumour, immunotherapy, radiotherapy, thermal ablation of the tumour and combinations thereof.
  • the at least one chemotherapy drug is selected from: temozolamide, paclitaxel, nab-paclitaxel, folfirinox, epirubicin, capecitabine, oxaliplatin, prostate hormone therapy, and EGFR inhibitor drugs.
  • the at least one therapy is surgery or radiotherapy.
  • a fifth aspect of the present invention relates to a method for preventing or treating a tumour, preferably a malignant tumour, which expresses the human protein Glypican-1 .
  • a tumour preferably a malignant tumour, which expresses the human protein Glypican-1 .
  • the tumour is a tumour that overexpresses the human protein Glypican-1.
  • the tumour is selected from: glioblastoma, prostate cancer, oesophageal cancer and pancreatic cancer, preferably pancreatic carcinoma, even more preferably pancreatic ductal adenocarcinoma.
  • said method comprises at least a step of administering a compound or composition or human protein Glypican-1 as described above in detail to an individual who has a need therefor.
  • the compound or composition or human protein Glypican-1 as described above in detail is administered orally, for example formulated as a spray for oral use or as a tablet or as orodispersible granules.
  • the compound or composition or human protein Glypican-1 as described above in detail is administered parenterally, preferably subcutaneously.
  • a sixth aspect of the present invention relates to a method for stimulating the immune system of an individual against the cancer antigen Glypican-1.
  • said method comprises at least a step of administering a compound or composition or human protein Glypican-1 as described above in detail to an individual who has a need therefor.
  • the compound or composition or human protein Glypican-1 as described above in detail is administered orally, for example formulated as a spray for oral use or as a tablet or as orodispersible granules.
  • the compound or composition or human protein Glypican-1 as described above in detail is administered parenterally, preferably subcutaneously.
  • the immunogenic sequence (SEQ ID NO:1 ) as described above was inserted into an expression vector of the immunogenic peptide in the probiotic bacterium E. Coli Nissle.
  • the vector was then used for the transformation of E. Coli Nissle by electroporation.
  • the ability of the probiotic vector to express the immunogenic protein of interest was evaluated by western blot. This analysis made it possible to check both that the immunogenic protein had the expected size, i.e. that it had the right conformation, and that the immunogenic protein was expressed in relevant quantities and thus useful for a possible use of the probiotic for a vaccine approach with oral administration.
  • the bacteria were centrifuged and then the precipitate was lysed using Hepes 25 mM, 0.2 M NaCI 5% glycerol. Sonication was then carried out and the preparations were loaded into a 10% polyacrylamide gel (Figure 1 ).
  • Figure 1 the probiotic bacterium E. Coli Nissle transformed with the vector into which the immunogenic sequence in question was inserted is capable of producing large quantities of the protein of interest.
  • the wells corresponding to the preparation of the untransformed E. Coli Nissle bacterium do not show any band ( Figure 1 ).
  • mice C57BL/6JOIaHsd.
  • Two groups of mice were used.
  • the ability of the vaccine vector to induce an anti-Glypican-1 immunogenic response with oral administration of the vaccine vector was evaluated.
  • a first group of mice had the administration of E. Coli Nissle bacteria transformed to express the immunogenic peptide in order to generate an anti-Glypican-1 response; another group of mice, representing the control, had oral administration of untransformed bacteria.
  • mice in both groups were tested by flow cytometry on cells belonging to the pancreatic ductal adenocarcinoma cell line BXPC3 expressing GPC1 and on cells belonging to the T-cell leukaemia Jurkat cell line used as a control.
  • the serum of mice to which the E. Coli Nissle bacteria expressing the immunogenic peptide of interest were administered showed positivity for cells expressing Glypican-1 and were thus able to recognise the protein of eukaryotic origin Glypican-1.
  • the serum of the mice in this group did not show positivity for Jurkat cells, cells that do not express the protein Glypican-1 .
  • Coli Nissle bacterium expressing the protein immunogenic towards Glypican-1 was administered.
  • the mice in the group to which untransformed E. Coli Nissle bacteria were administered did not show an immune response that was specific for the protein Glypican-1 ( Figure 2).
  • ELISA enzyme-linked immunosorbent assay
  • Coli Nissle bacterial cells expressing the immunogenic peptide of interest when the levels in the collected sera were evaluated at different times (T14 days, T30 days and T45 days compared to the basal value prior to treatment (time 0 (TO)).
  • the ability of the vaccine vector consisting of E. Coli Nissle bacterial cells expressing the immunogenic peptide of interest to produce a concentration of antibodies specific for human Glypican- 1 using the oral route of administration was further evaluated by ELISA experiments. This evaluation was carried out in a group of mice, a first group of which received the vaccine vector consisting of 2*10 9 E. Coli Nissle bacterial cells expressing the immunogenic peptide (OS GPC1-Flag), administered orally through the uptake of feed.
  • OS GPC1-Flag immunogenic peptide
  • mice representing the negative control received, again through the uptake of feed, 2*10 9 of E. Coli Nissle WT bacterial cells (i.e. cells not expressing the immunogenic peptide) (OS WT).
  • a third group of mice was tested by subcutaneous vaccination with 5*10 8 of transformed bacteria lysed by heat (SC GPC1-Flag).
  • SC GPC1-Flag subcutaneous vaccination with 5*10 8 of transformed bacteria lysed by heat
  • the ELISA results show that through oral administration it was possible to obtain an anti-Glypican-1 antibody concentration.
  • OS GPC1-Flag This increase in orally treated mice (OS GPC1-Flag) is comparable to the increase in mice treated subcutaneously (SC GPC1-Flag). This increase was not detected, however, in mice to which the untransformed E. Coli Nissle bacterium (OS WT) was administered ( Figure 3).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un composé choisi parmi un polynucléotide codant pour le glypican-1, un vecteur, et une cellule hôte génétiquement modifiée de façon à exprimer le glypican-1. La présente invention concerne en outre l'utilisation du composé pour la prévention ou le traitement d'une tumeur.
PCT/IB2023/060036 2022-10-06 2023-10-06 Composition de vaccin contre le cancer qui comprend une cellule hôte exprimant le glypican-1 (gpc-1) Ceased WO2024075067A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102022000020571 2022-10-06
IT102022000020571A IT202200020571A1 (it) 2022-10-06 2022-10-06 Nuovo composto

Publications (1)

Publication Number Publication Date
WO2024075067A1 true WO2024075067A1 (fr) 2024-04-11

Family

ID=84943922

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/060036 Ceased WO2024075067A1 (fr) 2022-10-06 2023-10-06 Composition de vaccin contre le cancer qui comprend une cellule hôte exprimant le glypican-1 (gpc-1)

Country Status (2)

Country Link
IT (1) IT202200020571A1 (fr)
WO (1) WO2024075067A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015106311A1 (fr) * 2014-01-17 2015-07-23 Minomic International Ltd. Antigène de surface cellulaire du cancer de la prostate destiné au diagnostic
US20150359909A1 (en) * 2009-07-16 2015-12-17 University College Cork-National University Of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
WO2018129404A1 (fr) * 2017-01-06 2018-07-12 Synlogic, Inc. Micro-organismes programmés pour produire des immunomodulateurs et des agents thérapeutiques anticancéreux dans des cellules tumorales
EP3617231A1 (fr) * 2017-04-28 2020-03-04 National University Corporation Kochi University Anticorps anti-gpc-1
WO2021242798A1 (fr) * 2020-05-26 2021-12-02 Synlogic Operating Company, Inc. Affichage de surface de protéines sur des bactéries recombinantes et leurs utilisations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150359909A1 (en) * 2009-07-16 2015-12-17 University College Cork-National University Of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
WO2015106311A1 (fr) * 2014-01-17 2015-07-23 Minomic International Ltd. Antigène de surface cellulaire du cancer de la prostate destiné au diagnostic
WO2018129404A1 (fr) * 2017-01-06 2018-07-12 Synlogic, Inc. Micro-organismes programmés pour produire des immunomodulateurs et des agents thérapeutiques anticancéreux dans des cellules tumorales
EP3617231A1 (fr) * 2017-04-28 2020-03-04 National University Corporation Kochi University Anticorps anti-gpc-1
WO2021242798A1 (fr) * 2020-05-26 2021-12-02 Synlogic Operating Company, Inc. Affichage de surface de protéines sur des bactéries recombinantes et leurs utilisations

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHEN KUN ET AL: "XCL1 / Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti-PD-1 Efficacy", CANCER IMMUNOLOGY RESEARCH, vol. 8, no. 1, 1 January 2020 (2020-01-01), US, pages 81 - 93, XP093115889, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-19-0210 *
KITAGAWA KOICHI ET AL: "An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model", MOLECULAR THERAPY - ONCOLYTICS, vol. 22, 25 August 2021 (2021-08-25), pages 592 - 603, XP093039665, ISSN: 2372-7705, DOI: 10.1016/j.omto.2021.08.009 *
LUND ET AL: "The Role of Glypican-1 in the Tumour Microenvironment", ANTI-INFLAMMATORY NUTRACEUTICALS AND CHRONIC DISEASES /ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY BOOK SERIES (AEMB); [ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY ISSN 2214-8019], SPRINGER, vol. 1245, 8 April 2020 (2020-04-08), pages 163 - 176, XP009541906, ISSN: 2214-8019, ISBN: 978-3-319-41332-7, DOI: 10.1007/978-3-030-40146-7_8 *
NISHIGAKI TAKAHIKO ET AL: "Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer", BRITISH JOURNAL OF CANCER, vol. 122, no. 9, 10 March 2020 (2020-03-10), pages 1333 - 1341, XP037401991, ISSN: 0007-0920, DOI: 10.1038/S41416-020-0781-2 *
S VIAUD ET AL: "Gut microbiome and anticancer immune response: really hot Sh*t!", CELL DEATH & DIFFERENTIATION, vol. 22, no. 2, 16 May 2014 (2014-05-16), GB, pages 199 - 214, XP055227164, ISSN: 1350-9047, DOI: 10.1038/cdd.2014.56 *
SATOKO MATSUZAKI ET AL: "Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer : Antitumor activity of an ADC targeting glypican-1", INTERNATIONAL JOURNAL OF CANCER, vol. 142, no. 5, 1 March 2018 (2018-03-01), US, pages 1056 - 1066, XP055516974, ISSN: 0020-7136, DOI: 10.1002/ijc.31124 *
SCHLAEPFER SALES CAROLINE B. ET AL: "Glypican-1, -3, -5 (GPC1, GPC3, GPC5) and Hedgehog Pathway Expression in Oral Squamous Cell Carcinoma", APPLIED IMMUNOHISTOCHEMSITRY AND MOLECULAR MORPHOLOGY, vol. 29, no. 5, 1 May 2021 (2021-05-01), US, pages 345 - 351, XP093039938, ISSN: 1541-2016, Retrieved from the Internet <URL:http://dx.doi.org/10.1097/PAI.0000000000000907> DOI: 10.1097/PAI.0000000000000907 *
TANIGUCHI MASATAKE ET AL: "Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis", vol. 111, no. 8, 18 June 2020 (2020-06-18), JP, pages 2747 - 2759, XP093039538, ISSN: 1347-9032, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cas.14497> DOI: 10.1111/cas.14497 *
TOMASI MICHELE ET AL: "Commensal Bifidobacterium Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines", VACCINES, vol. 9, no. 11, 18 November 2021 (2021-11-18), pages 1356, XP093039664, DOI: 10.3390/vaccines9111356 *
WU QUNFENG ET AL: "A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma", vol. 25, no. 10, 10 August 2017 (2017-08-10), US, pages 2299 - 2308, XP093039466, ISSN: 1525-0016, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628867/pdf/main.pdf> DOI: 10.1016/j.ymthe.2017.08.005 *

Also Published As

Publication number Publication date
IT202200020571A1 (it) 2024-04-06

Similar Documents

Publication Publication Date Title
ES2905591T3 (es) Plataforma de estructura de núcleo/cáscara para inmunoterapia
Chorobik et al. Salmonella and cancer: from pathogens to therapeutics
US9744224B2 (en) Methods for treating cancer by administration of nucleic acids encoding FAP and cancer antigens
Shende et al. Recent trends and advances in microbe-based drug delivery systems
RS57630B1 (sr) Metode i sastavi za uzrokovanje imunog odgovora na egfrviii
US20220273782A1 (en) Novel PD-L1 Targeting DNA Vaccine for Cancer Immunotherapy
ES2398492T3 (es) Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
CN108350411A (zh) 口服肿瘤疫苗
JP2021518129A (ja) 組成物
JP2012097109A (ja) 癌ワクチン中のアジュバントとしてのラクトフェリン
CN111154806A (zh) 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
US20210106652A1 (en) Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
Wang et al. Oral biomimetic virus vaccine hydrogel for robust abscopal antitumour efficacy
Gravekamp et al. Harnessing Listeria monocytogenes to target tumors
WO2024075067A1 (fr) Composition de vaccin contre le cancer qui comprend une cellule hôte exprimant le glypican-1 (gpc-1)
Nathalie et al. Therapeutic MUC1-based cancer vaccine expressed in flagella-efficacy in an aggressive model of breast cancer
Fialho et al. Recent patents on bacterial proteins as potential anticancer agents
CN116948038A (zh) 用于诱导肿瘤特异性免疫应答的重组抗原肽及重组李斯特菌
KR102514849B1 (ko) 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물
US20250302975A1 (en) Methods and compositions for agonising tlr3
AU2021226544B2 (en) Tumor immune enhancer, and preparation method therefor and application thereof
KR100933090B1 (ko) 점착성 융합단백질 및 이를 이용한 가축의 설사증 예방또는 치료용 면역보조제
US20190343965A1 (en) Phage conjugates and uses thereof
Kelly The Immunoengineering Toolbox: A Set of Thermoresponsive Biopolymers for Sustained Delivery of Cancer Immunotherapies
WO2025109155A1 (fr) Variant d&#39;interleukine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23801868

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23801868

Country of ref document: EP

Kind code of ref document: A1